Subtype
Genitourinary System Carcinoma
CI-CAN-00000925Explore in graph →
1,498 active trials44 approved drugs143 evidence items
- NCIt
- C164141
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000925Explore in graph →
Clinical trials
4,916 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (758)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04502095 | Prophylactic Antibiotics for Urinary Tract Infections After Robot-Assisted Radical Cystectomy | completed | Phase 4 | 89 | Roswell Park Cancer InstituteOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT03641560 | A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy | completed | Phase 4 | 52 | Astellas Pharma IncINDUSTRY | 1 | Jun 24, 2026 |
| clinicaltrials |
| NCT02555748 | Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma(SUP-R) | completed | Phase 4 | 47 | Institut Claudius RegaudOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT02405858 | A Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Participants Who Responded Poorly to the First-line Combined Androgen Blockade Therapy | completed | Phase 4 | 51 | Janssen Pharmaceutical K.K.INDUSTRY | 1 | Feb 3, 2025 | clinicaltrials |
| NCT01977651 | A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide(UPWARD) | completed | Phase 4 | 424 | Astellas Pharma Global Development, Inc.INDUSTRY | 20 | Dec 6, 2024 | clinicaltrials |
| NCT02116582 | A Study to Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate Cancer | completed | Phase 4 | 215 | Astellas Pharma Europe B.V.INDUSTRY | 5 | Dec 6, 2024 | clinicaltrials |
| NCT05803096 | Self-Administered Nitrous Oxide (SANO) During Transrectal Prostate Biopsy to Reduce Patient Anxiety and Pain | completed | Phase 4 | 143 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jan 30, 2024 | clinicaltrials |
| NCT02982954 | A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer(CHECKMATE 920) | completed | Phase 4 | 211 | Bristol-Myers SquibbINDUSTRY | 1 | Nov 1, 2022 | clinicaltrials |
| NCT02596035 | An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma(CheckMate 374) | completed | Phase 4 | 197 | Bristol-Myers SquibbINDUSTRY | 1 | Oct 27, 2022 | clinicaltrials |
| NCT04197089 | Biological Effect of Vitamin D in Patients With Urothelial Carcinoma(VitDURO) | completed | Phase 4 | 2 | Germans Trias i Pujol HospitalOTHER | 1 | Aug 3, 2022 | clinicaltrials |
| NCT03525834 | Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex. | completed | Phase 4 | 40 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 9, 2021 | clinicaltrials |
| NCT00414765 | Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma | completed | Phase 4 | 26 | Novartis PharmaceuticalsINDUSTRY | 1 | Jun 8, 2021 | clinicaltrials |
| NCT03105856 | FASTER-Tlalpan Study in Mexico: HPV Vaccination Impact on Cervical Cancer Screening Program(FASTER) | completed | Phase 4 | 3,000 | Instituto Nacional de Salud Publica, MexicoOTHER | 1 | Aug 10, 2020 | clinicaltrials |
| NCT01206764 | A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma. | completed | Phase 4 | 143 | Novartis PharmaceuticalsINDUSTRY | 10 | Jun 24, 2019 | clinicaltrials |
| NCT02214602 | Value of Immediate Post-operative Intravesical Epirubicin in Intermediate&High Risk Non Muscle Invasive Bladder Cancer(NMIBCIVT) | completed | Phase 4 | 240 | Mansoura UniversityOTHER | 1 | Mar 22, 2018 | clinicaltrials |
| NCT02025361 | Impact of Local Anesthesia Type on Cancer Detection Rate in Transrectal Ultrasound Guided Prostate Biopsy | completed | Phase 4 | 422 | Bagcilar Training and Research HospitalOTHER_GOV | 1 | Jan 18, 2018 | clinicaltrials |
| NCT01266837 | Open Label, Single Arm Trial to Characterize Patients With Metastatic RCC Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2)(MARC-2) | completed | Phase 4 | 64 | iOMEDICO AGINDUSTRY | 1 | Nov 14, 2017 | clinicaltrials |
| NCT01521715 | First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma(FLIPPER) | completed | Phase 4 | 44 | iOMEDICO AGINDUSTRY | 1 | Aug 23, 2017 | clinicaltrials |
| NCT01514448 | Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib | completed | Phase 4 | 29 | Novartis PharmaceuticalsINDUSTRY | 1 | Jul 19, 2017 | clinicaltrials |
| NCT00172003 | Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis | completed | Phase 4 | 50 | Novartis PharmaceuticalsINDUSTRY | 1 | Nov 18, 2016 | clinicaltrials |
| NCT01402089 | Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients | completed | Phase 4 | 54 | Markus JoergerOTHER | 1 | Feb 2, 2016 | clinicaltrials |
| NCT02056587 | Everolimus in Patients With Metastatic Renal Cell Carcinoma Following Progression on Prior Bevacizumab Treatment | completed | Phase 4 | 37 | Kidney Cancer Research BureauOTHER | 1 | Feb 6, 2014 | clinicaltrials |
| NCT00706706 | Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma(MRCC RCC) | completed | Phase 4 | 105 | PfizerINDUSTRY | 1 | Jan 18, 2013 | clinicaltrials |
Data updated 1 hour agoSource updated Sep 29, 2026source: clinicaltrials